See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $114B | 9.9x | 34.5x | |
| $10.5B | 3.5x | 13.4x | |
| $4.1B | 12.6x | 30.3x | |
| $3.7B | 10.7x | 28.4x | |
| $3.1B | 79.0x | -6.9x | |
| $2.6B | 709.0x | -64.7x | |
| $2.1B | 3.7x | 34.8x | |
| $1.8B | 6.9x | 28.0x | |
| $1.6B | 73.8x | -34.7x | |
| $1.5B | n/a | n/a | |
| $1.0B | 1678.6x | -42.2x | |
| $995M | 17.1x | -2.3x | |
| $905M | 2.5x | 11.7x | |
| $841M | 14.9x | -1.8x | |
| $611M | 1.3x | 12.0x | |
| $586M | 8.2x | 28.9x | |
| $576M | 2.8x | 25.8x | |
| $489M | 17.3x | -3.0x | |
| $474M | n/a | n/a | |
| $440M | 12.3x | 24.9x | |
| $328M | 77.4x | n/a | |
| $309M | 255.4x | n/a | |
| $268M | n/a | n/a | |
| $184M | 15.6x | -2.5x | |
| $183M | n/a | n/a | |
| $180M | 22.6x | -7.6x | |
| $180M | 6.3x | 12.8x | |
| $177M | 28.7x | -55.7x | |
| $174M | 0.5x | n/a | |
| $145M | 1039.1x | -0.8x | |
| $133M | 1.2x | 18.8x | |
| $125M | 2.3x | 39.9x | |
| $121M | n/a | n/a | |
| $99.0M | n/a | n/a | |
| $91.1M | 3.4x | -7.4x | |
| $78.0M | n/a | n/a | |
| $73.8M | n/a | -5.2x | |
| $67.0M | 239.4x | -0.3x | |
| $47.5M | 33.9x | n/a | |
| $25.5M | n/a | n/a | |
| $24.2M | n/a | n/a | |
| $18.7M | 4.6x | n/a | |
| $15.3M | 16.9x | -3.1x | |
| $15.3M | 2.5x | n/a | |
| $10.1M | 4.9x | n/a | |
| -$163M | -2.7x | 0.9x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine